Advertisement

Hypereosinophiles Syndrom und weitere rheumatische Erkrankungen mit Hypereosinophilie

  • J. H. SchirmerEmail author
  • B. F. Hoyer
Leitthema

Zusammenfassung

Unter den von Rheumatologen behandelten eosinophilen Krankheitsbildern kommen neben der eosinophilen Granulomatose mit Polyangiitis weitere organbezogene oder Systemerkrankungen mit Hypereosinophilie vor. Erst die exakte differenzialdiagnostische Abgrenzung der Erkrankungen ermöglicht eine pathogenetisch orientierte Therapie. In diesem Beitrag werden als Schwerpunkt die hypereosinophilen Syndrome behandelt. Als mögliche Differenzialdiagnosen werden die Ig(Immunglobulin)G4-assoziierte Erkrankung, die eosinophile Fasziitis, medikamenteninduzierte Vaskulitiden sowie das Eosinophilie-Myalgie-Syndrom und Toxic-Oil-Syndrom als historische medikamenteninduzierte entzündlich rheumatische Erkrankungen beschrieben und ihr klinisches Bild und ihre Therapie zusammenfassend dargestellt.

Schlüsselwörter

IgG4-assoziierte Erkrankung Eosinophile Fasziitis Medikamenteninduzierte Vaskulitis Eosinophilie-Myalgie-Syndrom Toxic-Oil-Syndrom 

Hypereosinophilic syndrome and other rheumatic diseases with hypereosinophilia

Abstract

Among the eosinophilic diseases treated by rheumatologists other than eosinophilic granulomatosis with polyangiitis, there are further organ-related and systemic diseases with hypereosinophilia. Only the exact differential diagnostic demarcation of the diseases enables a pathogenetic oriented treatment. This article focuses on the hypereosinophilic syndromes. The potential differential diagnoses of Ig(immunoglobulin)G4-related disease, eosinophilic fasciitis and drug-induced vasculitis as well as eosinophilia-myalgia syndrome and toxic oil syndrome as historic drug-induced inflammatory rheumatic diseases are described and the clinical manifestations and treatment are summarized.

Keywords

IgG4-related disease Eosinophilic fasciitis Drug-induced vasculitis Eosinophilia-myalgia syndrome Toxic oil syndrome 

Notes

Einhaltung ethischer Richtlinien

Interessenkonflikt

J.H. Schirmer und B.F. Hoyer geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Literatur

  1. 1.
    Allen JA, Peterson A, Sufit R et al (2011) Post-epidemic eosinophilia-myalgia syndrome associated with L‑tryptophan. Arthritis Rheum 63:3633–3639.  https://doi.org/10.1002/art.30514 CrossRefPubMedGoogle Scholar
  2. 2.
    Belongia EA, Hedberg CW, Gleich GJ et al (1990) An investigation of the cause of the eosinophilia-myalgia syndrome associated with tryptophan use. N Engl J Med 323:357–365.  https://doi.org/10.1056/NEJM199008093230601 CrossRefPubMedGoogle Scholar
  3. 3.
    Carruthers MN, Park S, Slack GW et al (2017) IgG4-related disease and lymphocyte-variant hypereosinophilic syndrome: a comparative case series. Eur J Haematol 98:378–387.  https://doi.org/10.1111/ejh.12842 CrossRefPubMedGoogle Scholar
  4. 4.
    Carruthers MN, Topazian MD, Khosroshahi A et al (2015) Rituximab for IgG4-related disease: a prospective, open-label trial. Ann Rheum Dis 74:1171–1177.  https://doi.org/10.1136/annrheumdis-2014-206605 CrossRefPubMedGoogle Scholar
  5. 5.
    Chusid MJ, Dale DC, West BC, Wolff SM (1975) The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore) 54:1–27CrossRefGoogle Scholar
  6. 6.
    Cottin V, Bel E, Bottero P et al (2017) Revisiting the systemic vasculitis in eosinophilic granulomatosis with polyangiitis (Churg-Strauss): A study of 157 patients by the Groupe d’Etudes et de Recherche sur les Maladies Orphelines Pulmonaires and the European Respiratory Society Taskforce on eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Autoimmun Rev 16:1–9.  https://doi.org/10.1016/j.autrev.2016.09.018 CrossRefPubMedGoogle Scholar
  7. 7.
    Deshpande V, Zen Y, Chan JK et al (2012) Consensus statement on the pathology of IgG4-related disease. Mod Pathol 25:1181–1192.  https://doi.org/10.1038/modpathol.2012.72 CrossRefPubMedGoogle Scholar
  8. 8.
    Groh M, Pagnoux C, Baldini C et al (2015) Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. Eur J Intern Med 26:545–553.  https://doi.org/10.1016/j.ejim.2015.04.022 CrossRefPubMedGoogle Scholar
  9. 9.
    Hertzman PA, Blevins WL, Mayer J et al (1990) Association of the eosinophilia-myalgia syndrome with the ingestion of tryptophan. N Engl J Med 322:869–873.  https://doi.org/10.1056/NEJM199003293221301 CrossRefPubMedGoogle Scholar
  10. 10.
    James TN (1994) The toxic oil syndrome. Clin Cardiol 17:463–470CrossRefGoogle Scholar
  11. 11.
    Jennette JC, Falk RJ, Bacon PA et al (2013) 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65:1–11.  https://doi.org/10.1002/art.37715 CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Khosroshahi A, Wallace ZS, Crowe JL et al (2015) International consensus guidance statement on the management and treatment of IgG4-related disease. Arthritis Rheumatol 67:1688–1699.  https://doi.org/10.1002/art.39132 CrossRefPubMedGoogle Scholar
  13. 13.
    Klion AD (2015) How I treat hypereosinophilic syndromes. Blood 126:1069–1077.  https://doi.org/10.1182/blood-2014-11-551614 CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Lefèvre G, Ackermann F, Kahn J‑E (2017) Hypereosinophilia with asthma and systemic (non-vasculitic) manifestations: eosinophilic granulomatosis with polyangiitis or hypereosinophilic syndrome? Autoimmun Rev 16:208–209.  https://doi.org/10.1016/j.autrev.2016.11.001 CrossRefPubMedGoogle Scholar
  15. 15.
    Masi AT, Hunder GG, Lie JT et al (1990) The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 33:1094–1100CrossRefGoogle Scholar
  16. 16.
    Mertens JS, Seyger MMB, Thurlings RM et al (2017) Morphea and eosinophilic fasciitis: an update. Am J Clin Dermatol 18:491–512.  https://doi.org/10.1007/s40257-017-0269-x CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Ogbogu PU, Bochner BS, Butterfield JH et al (2009) Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol 124:1319–1325.e3.  https://doi.org/10.1016/j.jaci.2009.09.022 CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Pendergraft WF, Niles JL (2014) Trojan horses: drug culprits associated with antineutrophil cytoplasmic autoantibody (ANCA) vasculitis. Curr Opin Rheumatol 26:42–49.  https://doi.org/10.1097/BOR.0000000000000014 CrossRefPubMedGoogle Scholar
  19. 19.
    Perugino CA, Mattoo H, Mahajan VS et al (2017) Emerging treatment models in rheumatology: IgG4-related disease: insights into human immunology and targeted therapies. Arthritis Rheumatol 69:1722–1732.  https://doi.org/10.1002/art.40168 CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Reiter A, Gotlib J (2017) Myeloid neoplasms with eosinophilia. Blood 129:704–714.  https://doi.org/10.1182/blood-2016-10-695973 CrossRefPubMedGoogle Scholar
  21. 21.
    Reyes F, Vaitkus V, Al-Ajam M (2018) A case of cocaine-induced eosinophilic pneumonia: case report and review of the literature. Respir Med Case Rep 23:98–102.  https://doi.org/10.1016/j.rmcr.2017.12.012 CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Rothenberg ME, Klion AD, Roufosse FE et al (2008) Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med 358:1215–1228.  https://doi.org/10.1056/NEJMoa070812 CrossRefPubMedGoogle Scholar
  23. 23.
    Roufosse F (2018) Targeting the Interleukin-5 pathway for treatment of Eosinophilic conditions other than asthma. Front Med 5:49.  https://doi.org/10.3389/fmed.2018.00049 CrossRefGoogle Scholar
  24. 24.
    Roufosse FE, Goldman M, Cogan E (2007) Hypereosinophilic syndromes. Orphanet J Rare Dis 2:37.  https://doi.org/10.1186/1750-1172-2-37 CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Schirmer JH, Aries PM, de Groot K et al (2017) S1 guidelines Diagnostics and treatment of ANCA-associated vasculitis. Z Rheumatol 76:77–104.  https://doi.org/10.1007/s00393-017-0394-1 CrossRefPubMedGoogle Scholar
  26. 26.
    Silver RM, Heyes MP, Maize JC et al (1990) Scleroderma, fasciitis, and eosinophilia associated with the ingestion of tryptophan. N Engl J Med 322:874–881.  https://doi.org/10.1056/NEJM199003293221302 CrossRefPubMedGoogle Scholar
  27. 27.
    Simon H‑U, Klion A (2012) Therapeutic approaches to patients with hypereosinophilic syndromes. Semin Hematol 49:160–170.  https://doi.org/10.1053/j.seminhematol.2012.01.002 CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Simon H‑U, Rothenberg ME, Bochner BS et al (2010) Refining the definition of hypereosinophilic syndrome. J Allergy Clin Immunol 126:45–49.  https://doi.org/10.1016/j.jaci.2010.03.042 CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Stone JH, Khosroshahi A, Deshpande V et al (2012) Recommendations for the nomenclature of IgG4-related disease and its individual organ system manifestations. Arthritis Rheum 64:3061–3067.  https://doi.org/10.1002/art.34593 CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Stone JH, Zen Y, Deshpande V (2012) IgG4-related disease. N Engl J Med 366:539–551.  https://doi.org/10.1056/NEJMra1104650 CrossRefPubMedGoogle Scholar
  31. 31.
    Torre DE, Mattoo H, Mahajan VS et al (2014) Prevalence of atopy, eosinophilia, and IgE elevation in IgG4-related disease. Arerugi 69:269–272.  https://doi.org/10.1111/all.12320 CrossRefGoogle Scholar
  32. 32.
    Valent P, Klion AD, Horny H‑P et al (2012) Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol 130:607–612.e9.  https://doi.org/10.1016/j.jaci.2012.02.019 CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Wallace ZS, Deshpande V, Mattoo H et al (2015) IgG4-related disease: clinical and laboratory features in one hundred twenty-five patients. Arthritis Rheumatol 67:2466–2475.  https://doi.org/10.1002/art.39205 CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Wechsler ME, Akuthota P, Jayne D et al (2017) Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N Engl J Med 376:1921–1932.  https://doi.org/10.1056/NEJMoa1702079 CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2019

Authors and Affiliations

  1. 1.Klinik für Innere Medizin I, Sektion Rheumatologie, Exzellenzzentrum EntzündungsmedizinUniversitätsklinikum Schleswig-Holstein, Campus KielKielDeutschland

Personalised recommendations